Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152684 | 0.90 | SLC5A2 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL30529877 | 0.86 | CYP2A6 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL155560 | 0.86 | CYP2A6 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL155572 | 0.85 | SLC5A2 (0.49) | CYP2C9CYP2C19SLC5A2ABCB11ADORA3 | |
| SCHEMBL156898 | 0.85 | SLC5A2 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP2D6 | |
| SCHEMBL155881 | 0.83 | SLC5A2 (0.40) | MEN1KMT2ACYP2C9CYP2C19SLC5A2 | |
| SCHEMBL152991 | 0.82 | SLC5A2 (0.39) | SMN1; SMN2MEN1KMT2ACYP2D6CYP2C9 | |
| SCHEMBL154701 | 0.81 | SLC5A2 (0.54) | ALDH1A1SMN1; SMN2KDM4ESLC5A2ABCB11 | |
| SCHEMBL29366717 | 0.81 | SLC5A2 (0.54) | ALDH1A1SMN1; SMN2KDM4ESLC5A2ABCB11 | |
| SCHEMBL152479 | 0.81 | HDAC6 (0.42) | SMN1; SMN2MEN1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2514756-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | ALDH1A1 831/4885SMN1; SMN2 3266/4885MEN1 539/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ALDH1A1 873/4885SMN1; SMN2 3474/4885MEN1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.